·论着·JMedRes,February2024,Vol.53No.2国产PD-1抑制剂联合仑伐替尼治疗老年晚期肝癌回顾性分析于丹丹王黎袁惠芳潘静连慧娟摘要目的探讨国产程序性细胞死亡蛋白-1（programmeddeath-1,PD-1)抑制剂联合仑伐替尼治疗老年晚期肝癌患者的临床疗效及安全性。方法收集2021年9月～2022年7月于郑州颐和医院接受国产PD-1抑制剂联合仑伐替尼治疗的37例老年（60岁以上）晚期肝癌患者的临床资料，采用实体瘤改良疗效评价标准（ModifiedResponseEvaluationCriteriainSolidTumors，mRECIST）评价肝内病灶疗效，采用实体瘤疗效评价标准（ResponseEvaluationCriteriainSolidTumors，RECIST）1.1版评价转移灶疗效。采用Kaplan-Meier法绘制生存曲线。结果37例老年晚期肝癌患者中,肿瘤部分缓解8例,疾病稳定15例,肿瘤进展14例，客观缓解率和疾病控制率分别为21.6%（8/37）和62.2%（23/37），中位无进展生存期为5.885个月（95%CI:5.374~6.397个月）。总体治疗相关不良反应的发生率为51.4%（19/37），疲乏27.0%（10/37）、皮疹27.0%（10/37）和高血压21.6%（8/37)是最常见的不良反应。结论国产PD-1抑制剂联合仑伐替尼治疗老年晚期肝癌疗效可,安全性好。关键词肝癌老年PD-1/PD-LI抑制剂仑伐替尼中图分类号R735RetrospectiveAnalysisofAdvancedHepatocellularCarcinomaintheElderlyTreatedwithDomesticPD-1InhibitorscombinedwithLenva-tinib.YUDandan,WANGLi,YUANHuifang,etal.DepartmentofOncology,ZhengzhouYiheHospital,Henan450000,ChinaAbstractObjectiveToexploretheclinicalefficacyandsafetyofdomesticprogrammeddeath-1(PD-1)ingibitorcombinedwithlenvatinibinthetreatmentofadvancedhepatocellularcarcinomaintheelderly.MethodsTheclinicaldataof37elderlypatients(o-ver60yearsold)withadvancedhepatocellularcarcinoma,whoreceiveddomesticPD-1inhibitorscombinedwithlenvatinibinZhengzhouYiheHospitalfromSeptember2021toJuly2022werecollected.ModifiedResponseEvaluationCriteriainSolidTumors(mRECIST)wasusedtoevaluatetheefficacyofintrahepaticlesions,andResponseEvaluationCriteriainSolidTumors(RECIST)1.1wasusedtoevaluatetheefficacyofextrahepaticmetastaticlesions.Kaplan-Meiermethodwasusedtoevaluatethesurvivalcurve.ResultsAmongthe37elderlypatientswithhepatocellularcarcinoma,8patientsachievedpartialresponse,15patientsachiev...
